KOL Insight Archives | Page 2 of 14 | Report Store

Bladder Cancer KOL Interview – US

A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

May 31, 2019

Find out more

ECLIPSE Psoriasis Pulse Survey

$599.00

This 11-question pulse survey of 74 dermatologists practicing throughout the US and Europe asks respondents their thoughts on results from the ECLIPSE study

January 31, 2019

Find out more

Colorectal Cancer KOL Interview – US

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.

October 29, 2020

Find out more

Post-AAIC KOL Interview

$599.00

Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

August 6, 2014

Find out more

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

June 30, 2020

Find out more

Psychiatry KOL Insight Interview

$599.00

At SfN, they showed some interesting preclinical data on the affect on the 5-HT7 and how it works in some animal models of cognition…especially those injected with PCPA. And you know in depression, they also did what we call the chronic mild stress (CMS)

January 24, 2014

Find out more

Pediatric Epilepsy KOL Interview – US, West

$599.00

A US expert in pediatric epilepsy provides insight into the approach to treating different forms of epilepsy. The key opinion leader (KOL) dives into the late-phase pipeline for epilepsy, as well as sharing insight into Epidiolex.

February 18, 2019

Find out more

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

$599.00

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.

August 28, 2020

Find out more

Datamonitor Healthcare Chronic Heart Failure KOL Interview – US, Southwest

$599.00

A US KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlanor and Entresto. Significant late-phase pipeline drugs are also covered, with a focus on SGLT-2 inhibitors.

February 4, 2019

Find out more

Alzheimer’s Disease KOL Interview – UK

$599.00

This interview with a UK key opinion leader (KOL) provides an overview of cost-effectiveness criteria that may be required to bring Alzheimer’s disease products successfully to the clinic in the UK. We also discuss current and potential treatment options, as well as unmet needs in Alzheimer’s disease.

January 20, 2019

Find out more

Ovarian Cancer Pulse Survey

$599.00

Diagnostics/diagnostic techniques discussed:

etarfolatide/folic acid, BRCA mutation testing

May 7, 2014

Find out more

Ovarian Cancer KOL Interview – UK

$599.00

A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include veliparib, mirvetuximab soravtansine, Recentin, ofranergene obadenovec, dostarlimab, Tecentriq, Keytruda, Imfinzi, and Opdivo.

April 2, 2020

Find out more

Key Questions in Immuno-Oncology

$1,099.00

This KOL survey answers key questions about current immunotherapy treatments and future trends in the immuno-oncology space.

August 8, 2018

Find out more

Datamonitor Schizophrenia KOL Interview

$599.00

On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

February 10, 2016

Find out more

Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

$599.00

In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more